Rebecca Nugent

EBRC President

Rebecca is an experienced R&D executive focused on commercializing research in the biotech industry enabling applications such as cell & gene therapies, synthetic biology and genomics. Dr. Nugent is currently the VP of HTP Operations at Tessera Therapeutics. Prior to Tessera, she led the research department at Synthego, developing novel technologies for genome engineering with a focus on human cell and gene therapies. Prior to Synthego, Rebecca spent six years at Twist Bioscience where she focused on the development of Synthetic Biology and Next-Generation Sequencing Target Enrichment (NGS TE) products. She did her Post-Doc at New England Biolabs and received her Ph.D. in Molecular Biology from the University of Southern California, where she studied yeast genetics with an emphasis on genomic stability.